A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
← catalyst calendarNCT05262400 · readout in 4 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
192actual
Sites
51
Countries
Argentina, Brazil, Bulgaria +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-14 | actual | When the study began enrolling |
| Primary completion | 2026-08-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-23 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-11-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Breast Cancer
- Solid Tumors
Interventions
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion
- Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion
- Drug: PF-07104091 + PF-07220060 + letrozole dose expansion
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
- Drug: PF-07220060 + PF-07104091 combination dose escalation
Primary outcomes
what the primary-completion date above is the date OFDose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle
measured Cycle 1 (28 days)
Number of participants with treatment emergent adverse events (AEs)
measured From baseline until end of study treatment or study completion (approximately 2 years)
Incidence of participants with clinical laboratory abnormalities
measured From baseline until end of study treatment or study completion (approximately 2 years)
Number of participants with vital signs abnormalities
measured From baseline until end of study treatment or study completion (approximately 2 years)
Number of participants with corrected QT (QTc) interval
measured From baseline until end of study treatment or study completion (approximately 2 years)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed